Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer

Immunotherapy for renal cell cancer (RCC) has witnessed several developments for more than two decades. Checkpoint inhibitors, including anti-CTLA-4 and anti-PD-1/PD-L1 blockers, have changed the treatment landscape for patients with advanced RCC in the past 3 years. Despite these advances, more tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xiaowen, Gan, Lu, Na, Aru, Ge, Lingling, Chen, Baoqing, Liu, Jiaming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906880/
https://www.ncbi.nlm.nih.gov/pubmed/31871454
http://dx.doi.org/10.1155/2019/1483406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906880/
https://www.ncbi.nlm.nih.gov/pubmed/31871454
http://dx.doi.org/10.1155/2019/1483406

Ejemplares similares